PassPort Technologies

PassPort Technologies is pioneering an active transdermal microporation platform designed to overcome the limitations of conventional drug patches. Its core technology painlessly creates microchannels in the skin's outer barrier, allowing for the delivery of larger molecules, including biologics and vaccines, via a simple patch. The company is leveraging the 505(b)(2) regulatory pathway for its lead preclinical CNS candidate and is pursuing partnerships to expand its pipeline. Its value proposition centers on needle-free administration, improved patient compliance, and potentially lower healthcare costs.

The PassPort® system is an active transdermal microporation platform. It uses a handheld applicator to deliver a pulse of energy through a disposable porator, painlessly creating microchannels in the skin's stratum corneum. A drug-loaded patch is then applied, enabling the delivery of a wide range of molecules, including biologics and vaccines, through these channels.

PassPort competes in the active transdermal enhancement market against technologies like microneedle arrays (e.g., Vaxxas, Micron Biomedical), thermal ablation (e.g., ViaDor), ultrasound (e.g., Echo Therapeutics), and chemical enhancers. Differentiation is based on painlessness, cost, breadth of deliverable molecules, and ease of self-administration.